Pharmacogenetics of b2-Agonists in Asthma.

Completed

Conditions studied: Asthma

In brief

This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).

Key facts

Study ID

NCT00708227

Run by

Nemours Children's Clinic

People needed

88

Starts

2007-09-01

Expected to finish

2012-08-01

Last updated by the study team

2018-02-22

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diplotype: Whites with specific diplotype and African Americans with specific diplotypes.
• Gender: Male or female. Women are eligible if they are not pregnant or lactating. Females subjects of childbearing potential will undergo a urine pregnancy test prior to each methacholine challenge test.
• Age: 10 years and older.
• Asthma Diagnosis: Physician diagnosed asthma according to American Thoracic Society criteria for at least 3 months.
• Asthma Therapy: There is no requirement for previous asthma therapy to be included in this study.
• Asthma Severity: forced expiratory volume in the first second (FEV1) must be >= 60% of predicted normal values for age, height, and gender.
• methacholine challenge test provocative concentration (20% fall in FEV1) of <=12]mg/ml.

You may not qualify if…

• History of life-threatening asthma: Any episode of asthma requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures.
• Asthma instability: Hospitalization for asthma within 3 months of Visit 1.
• Concurrent respiratory disease: Any respiratory disease other than asthma.
• Sensitivities: Sensitivities to methacholine, Flovent® MDI, ipratropium bromide, albuterol, or Advair Diskus® that would put the safety of the subject at risk.
• Respiratory Tract Infection: Any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection that has not resolved at least 2 weeks immediately preceding Visit 1, or for which antibiotic therapy has not been completed at least 2 weeks prior to Visit 1.
• Expected exposure to pollen allergen to which the patient is sensitive (by medical history of symptoms) during the 29 day study period. These patients can be studied when pollen exposure to which they are sensitive will not occur.

Where it is running

• Nemours Children's Clinic — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.